InspireMD, Inc. (NYSEMKT:NSPR) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2017, InspireMD, Inc. issued a press release announcing
its financial and operating results for the fiscal quarter ended
March 31, 2017. A copy of this press release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit
99.1, that is furnished to this Item 2.02 shall not be deemed to
be filed for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, and shall not be
incorporated by reference into any registration statement or
other document filed under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |
| 99.1 |
Press release dated May 9, 2017 (furnished herewith to Item 2.02). |
About InspireMD, Inc. (NYSEMKT:NSPR)
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device. InspireMD, Inc. (NYSEMKT:NSPR) Recent Trading Information
InspireMD, Inc. (NYSEMKT:NSPR) closed its last trading session down -0.005 at 0.625 with 142,427 shares trading hands.
